Determination of Plasma Heparin Level Improves Identification of Systemic Mast Cell Activation Disease
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Diagnosis of mast cell activation disease (MCAD), i.e. systemic mastocytosis (SM) and idiopathic systemic mast cell activation syndrome (MCAS), usually requires demonstration of increased mast cell (MC) mediator release. Since only a few MC mediators are currently established as biomarkers of MCAD, the sensitivity of plasma heparin level (pHL) as an indicator of increased MC activation was compared with that of serum tryptase, chromogranin A and urinary N-methylhistamine levels in 257 MCAD patients. Basal pHL had a sensitivity of 41% in MCAS patients and 27% in SM patients. Non-pharmacologic stimulation of MC degranulation by obstruction of venous flow for 10 minutes increased the sensitivity of pHL in MCAS patients to 59% and in SM patients to 47%. In MCAS patients tryptase, chromogranin A, and N-methylhistamine levels exhibited low sensitivities (10%, 12%, and 22%, respectively), whereas sensitivities for SM were higher (73%, 63%, and 43%, respectively). Taken together, these data suggest pHL appears more sensitive than the other mediators for detecting systemic MC activity in patients with MCAS. The simple, brief venous occlusion test appears to be a useful indicator of the presence of pathologically irritable MCs, at least in the obstructed compartment of the body.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, there are insuf fi cient data to demonstrate their clinical utility in the diagnosis of MCA and MCAS.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [76]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“approximately 80% of patients clinically demonstrating symptoms consistent with MCA showing increased levels of plasma heparin when measured using a sufficiently sensitive assay [58].”
From Diagnosis of mast cell activation syndrome: a global "consensus-2" (2021) · cites this paper as [58]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Like tryptase, heparin is highly (though not perfectly) specific to the MC [58]”
From Diagnosis of mast cell activation syndrome: a global "consensus-2" (2021) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H.-P., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Nuñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,108
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 2×
“SM is further divided into several subtypes [6].”
BackgroundMethodValent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Diagnostic Value of Tryptase in Anaphylaxis and Mastocytosis
Schwartz, L. B. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.05.010 · Cited by 477
Differential release of mast cell mediators and the pathogenesis of inflammation
Theoharides, T. C., Kempuraj, D., Tagen, M., Conti, P., & Kalogeromitros, D. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00519.x · Cited by 425
Álvarez-Twose, I., González de Olano, D., Sánchez-Muñoz, L., Matito, A., Esteban-López, M. I., Vega, A., Mateo, M. B., Alonso Díaz de Durana, M. D., de la Hoz, B., del Pozo Gil, M. D., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.02.019 · Cited by 294
Differential release of serotonin and histamine from mast cells
Theoharides, T. C., Bondy, P. K., Tsakalos, N. D., & Askenase, P. W. (1982) · Nature · doi:10.1038/297229a0 · Cited by 244
Epidemiology of systemic mastocytosis in Denmark
Cohen, S. S., Skovbo, S., Vestergaard, H., Kristensen, T., Møller, M., Bindslev‐Jensen, C., Fryzek, J. P., & Broesby‐Olsen, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.12916 · Cited by 234
Sperr, W. R., Jordan, J.-H., Fiegl, M., Escribano, L., Bellas, C., Dirnhofer, S., Semper, H., Simonitsch-Klupp, I., Horny, H.-P., & Valent, P. (2002) · International Archives of Allergy and Immunology · doi:10.1159/000059404 · Cited by 207
A Case of Intestinal Mastocytosis Misdiagnosed as Crohn's Disease
Reggiani, S., Cosso, L., Adriani, A., Pantaleoni, S., Risso, A., Vittone, F., Chiusa, L., Sapone, N., & Astegiano, M. (2015) · Case Reports in Gastroenterology · doi:10.1159/000430946 · Cited by 193
Research works printed but not linked: 2
- A Studer, 1954, Occurrence and significance of endogenous heparin, Experientia, 10, 148
- S Stefanov, 2013, Immunocytochemical expression of Chromogranin A in mast cells in the canine paranasal sinus, Revue Méd Vét, 164, 453
Cited by
Mast cell activation syndromes
Akin, C. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.06.007 · Cited by 177
Theoharides, T. C., Tsilioni, I., & Ren, H. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1596800 · Cited by 120
Valent, P., Bonadonna, P., Hartmann, K., Broesby-Olsen, S., Brockow, K., Butterfield, J. H., Triggiani, M., Lyons, J. J., Oude Elberink, J. N. G., Arock, M., et al. (2019) · International Archives of Allergy and Immunology · doi:10.1159/000501079 · Cited by 146
Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management
Castells, M., & Butterfield, J. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.02.002 · Cited by 135
Weiler, C. R., Austen, K. F., Akin, C., Barkoff, M. S., Bernstein, J. A., Bonadonna, P., Butterfield, J. H., Carter, M., Fox, C. C., Maitland, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.023 · Cited by 123
Diagnosis of mast cell activation syndrome: a global "consensus-2"
Afrin, L. B., Ackerley, M. B., Bluestein, L. S., Brewer, J. H., Brook, J. B., Buchanan, A. D., Cuni, J. R., Davey, W. P., Dempsey, T. T., Dorff, S. R., et al. (2021) · Diagnosis · doi:10.1515/dx-2020-0005 · Cited by 115
Self-citationMast cell disorders in Ehlers-Danlos syndrome
Seneviratne, S. L., Maitland, A., & Afrin, L. (2017) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31555 · Cited by 107
Characterization of Mast Cell Activation Syndrome
Afrin, L. B., Self, S., Menk, J., & Lazarchick, J. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.12.013 · Cited by 101
“All diagnoses met published criteria [history consistent with chronic/ recurrent aberrant MC mediator release affecting two or more organ systems, absence of any other evident disease (including mastocytosis) better accounting for all symptoms/findings in the case, and at least two elevated levels of mediators relativ…”
Gülen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, H. N. G., Butterfield, J. H., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2021.06.011 · Cited by 83
“Other potential markers that have been discussed in the context of MCA include heparin, serotonin, neuropeptides, platelet-activating factor, and chromogranin A (CgA).(13,71-76) However, there are insufficient data to demonstrate their clinical utility in the diagnosis of MCA and MCAS.”
BackgroundMast Cells, Mastocytosis, and Related Disorders
Theoharides, T. C., Valent, P., & Akin, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1510021 · Cited by 61
Mast Cell Activation Syndrome: A Primer for the Gastroenterologist
Weinstock, L. B., Pace, L. A., Rezaie, A., Afrin, L. B., & Molderings, G. J. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06264-9 · Cited by 59
Self-citationQuantification of human diamine oxidase
Boehm, T., Pils, S., Gludovacz, E., Szöllösi, H., Petroczi, K., Majdic, O., Quaroni, A., Borth, N., Valent, P., & Jilma, B. (2016) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2016.12.011 · Cited by 54
Mast cell mediators of significance in clinical practice in mastocytosis
Butterfield, J. H., Ravi, A., & Pongdee, T. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.04.011 · Cited by 48
Prevalence and risk factors for fragility fracture in systemic mastocytosis
Degboé, Y., Eischen, M., Nigon, D., Apoil, P.-A., Mailhol, C., Tournier, E., Laurent, C., Hanssens, K., Hermine, O., Paul, C., et al. (2017) · Bone · doi:10.1016/j.bone.2017.09.005 · Cited by 44
Nonclonal Mast Cell Activation Syndrome
Hamilton, M. J. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.04.002 · Cited by 40
Butterfield, J. H. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.03.008 · Cited by 27
Using the Right Criteria for MCAS
Gülen, T. (2024) · Current Allergy and Asthma Reports · doi:10.1007/s11882-024-01126-0 · Cited by 24
Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis
Seidel, H., Hertfelder, H.-J., Oldenburg, J., Kruppenbacher, J. P., Afrin, L. B., & Molderings, G. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168960 · Cited by 21
Self-citationValent, P., Akin, C., & Arock, M. (2024) · Current Allergy and Asthma Reports · doi:10.1007/s11882-024-01124-2 · Cited by 14
Chromogranin A is not a biomarker of mastocytosis
Hanjra, P., Lee, C.-C. R., Maric, I., Carter, M., Olivera, A., Metcalfe, D. D., & Komarow, H. D. (2018) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2017.08.022 · Cited by 10
“Other mediators where no such criteria have been proposed include heparin, histamine, and prostaglandin D2 and some authors have suggested chromogranin A (CgA) should be among these markers based on limited data;(2, 3).”
BackgroundMethodInfluentialSido, B., Homann, J., Hertfelder, H.-J., Zienkiewicz, T., Christians, K.-P., Schablin, P., Mücke, M., & Molderings, G. J. (2019) · Der Chirurg · doi:10.1007/s00104-019-0935-z · Cited by 6
Self-citationHaenisch, B., & Molderings, G. J. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0143-5 · Cited by 6
Self-citationCase Report: Treatment of systemic mastocytosis with sunitinib
Molderings, G. J., Afrin, L. B., Hertfelder, H.-J., & Brettner, S. (2017) · F1000Research · doi:10.12688/f1000research.13343.1 · Cited by 5
Self-citationThe roles of mast cells in allergic inflammation and mast cell-related disorders
Kim, H.-K. (2017) · Allergy Asthma & Respiratory Disease · doi:10.4168/aard.2017.5.5.248 · Cited by 5
Mast cell activation syndrome: High frequency of skin manifestations and anaphylactic shock
Casassa, E., Mailhol, C., Tournier, É., Laurent, C., Degboé, Y., Eischen, M., Kirsten, N., Moreau, J., Evrard, S., Mas, V. M., et al. (2018) · Allergology International · doi:10.1016/j.alit.2018.07.003 · Cited by 4
Molderings, G. J., Knüchel‐Clarke, R., Hertfelder, H.-J., & Kuhl, C. K. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.12.004 · Cited by 3
Self-citationRajendram, R., Al-Qahtani, A. H., & Sheikh, F. R. (2024) · Clinical Medicine · doi:10.1016/j.clinme.2024.100267 · Cited by 2
Recommendations for Improving the Diagnostic Criteria for Mast Cell Activation Syndrome
Coleman, C. L. (2023) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1
Wirz, S., Hertfelder, H.-J., Seidel, H., Homann, J., & Molderings, G. J. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121346
Self-citationUrinary Markers of Mast Cell Disease and Their Role in Diagnosis and Management
Butterfield, J. H., Pongdee, T., & Ravi, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-27820-5_4
Pathophysiological Drivers of Mast Cell Activation Syndrome and Implications for Treatment
Collins, S., Williams, T., Sanchez, E., & Agrawal, D. K. (2026) · Fortune Journal of Health Sciences · doi:10.26502/fjhs.427
Metadata
- Authors
- Vysniauskaite, M., Hertfelder, H.-J., Oldenburg, J., Dreßen, P., Brettner, S., Homann, J., & Molderings, G. J.
- Affiliations
- University Hospital Bonn (DE)
- St. Franziskus Hospital (DE)
- Corresponding author
- Molderings, Gerhard J.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-04-24
- Volume
- 10
- Issue
- 4
- Pages
- e0124912
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4409380
- OpenAlex
- W2093536852
- Cited by
- 30
- References
- 58
- Citations by year
- 2024: 3 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 7 · 2018: 4 · 2017: 8 · 2016: 2 · 2015: 1
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Keywords
- systemic mastocytosis, mast cell degranulation, venous occlusion test, tryptase, chromogranin A, N-methylhistamine, mast cell mediators, diagnostic sensitivity, biomarkers
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, Female, Heparin, Humans, Male, Mast Cells, Mastocytosis, Methylhistamines, Middle Aged, Sensitivity and Specificity, Reproducibility of Results, Biomarkers, Chromogranin A, Tryptases, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.